A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

计划入组 73 人 · 首次发布于 2025 年 12 月 2 日

Polymorphisms in ENAM, AMBN, and KLK4 Contribute to DCS.

计划入组 204 人 · 首次发布于 2024 年 4 月 3 日

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

计划入组 216 人 · 首次发布于 2021 年 5 月 24 日

KLK3 inhibitors(Merck)

KLK3/PSA(Myrio Therapeutics)

Anti-KLK5/KLK7 bispecific antibody(Genentech)

Radiopharm Theranostics Receives Ethics Approval for First-in-Human Trial of RAD 402 in Advanced Prostate Cancer

Triveni Bio Initiates Phase 2 Trial of Novel Anti-KLK5/7 Antibody TRIV-509 for Atopic Dermatitis

Juri Biosciences Secures Global Rights to KLK2-Targeted T-Cell Engager for Metastatic Prostate Cancer in $210M Deal